Селторексант (JNJ-42847922, JNJ-42847922-AAA)
Проводит Янссен Фармацевтика НВ
Страница компанииМногоцентровое, двойное слепое, рандомизированное, плацебо-контролируемое исследование, проводимое в параллельных группах для оценки эффективности и безопасности препарата селторексант в дозе 20 мг в качестве вспомогательного средства при лечении антидепрессантами взрослых и пожилых пациентов с большим депрессивным расстройством с симптомами бессонницы, у которых отсутствует адекватный ответ на терапию антидепрессантами, с периодом открытого долгосрочного продолжающегося лечения препаратом селторексант для оценки его безопасности
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/578/2020-10-05/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–74 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 100 чел. в стране «Россия».
- Центров в реестре: 8 в 5 городах. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс массы тела18–40 кг/м²
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 6
Критерии включения
- Meet Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders-Clinical Trials Version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months prior to randomization
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than \[>\] 0%) in depressive symptom severity with residual symptoms beyond insomnia present, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Body mass index (BMI) between 18 and 40 kilograms per meter square (kg/m\^2), inclusive (BMI = weight/height\^2)
- Participant must be medically stable on the basis of the following performed at screening: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Критерии невключения
- Has a recent (last 3 months) history of, or current signs and symptoms of, a) severe renal insufficiency (creatinine clearance \[CrCl\] <30 milliliter per minute \[mL/min\]); b) clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders; c) uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) for ideation on the Columbia Suicide Severity Rating Scale (C-SSRS), or a history of suicidal behavior within the past 6 months, as validated by the C-SSRS at screening or Day 1. Participants with prior suicidal behavior in the past year, or prior serious suicidal ideation/plan within the past 6 months, should be carefully screened. For current suicidal ideation, only participants with non serious items (1-3 of the suicidal ideation section of the C-SSRS) may be included at the discretion of the investigator
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, or somatoform disorders
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
Источник: ClinicalTrials.gov, NCT04533529 · запись обновлена в реестре 12 мая 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 9
- Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 — Baseline (Day 1), Day 43
- Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
- OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI) — From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)
- OL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline: Body Mass Index (BMI) — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Vital Signs: Temperature — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Weight — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Change From Baseline in Waist Circumference — OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52
- OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS) — From DB Baseline (Day 1) up to Week 52
Цель исследования
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.
Области и заболевания
Где проходит
8 центров в 5 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 578 от 05.10.2020 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04533529 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.